pravastatin has been researched along with rosuvastatin in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (50.00) | 29.6817 |
| 2010's | 8 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buckett, L; Davidson, R; Holdgate, G; McCormick, A; McTaggart, F; Schneck, D; Smith, G; Warwick, M | 1 |
| Carbonell, T; Freire, E | 1 |
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Askew, V; Auerbach, B; Bainbridge, G; Caspers, N; Choi, C; Dillon, L; Hanselman, JC; Harris, MS; Hutchings, R; Kowala, M; Larsen, SD; Lin, Z; Lu, GH; Park, W; Pavlovsky, A; Pfefferkorn, JA; Robertson, A; Sekerke, C; Tait, BD | 1 |
| Askew, V; Auerbach, B; Dillon, L; Hanselman, JC; Kennedy, RM; Kowala, MC; Larsen, SD; Lin, Z; Lu, GH; Miller, S; Park, WK; Robertson, A; Roth, BD; Sekerke, C; Song, Y; Steinbaugh, BA; Sun, K; Tait, BD; Trivedi, BK | 1 |
| Ahmad, S; Barrish, JC; Bird, E; Bisaha, S; Blanar, MA; Chang, M; Chen, BC; Chen, X; Cuff, CA; Darienzo, CJ; Giancarli, M; Harrity, T; Huang, C; Janovitz, E; Kennedy, LJ; Li, T; Madsen, CS; Monshizadegan, H; Ngu, K; Nguyen-Tran, V; Reeves, RA; Robl, JA; Ryan, CS; Search, D; Setters, R; Sitkoff, D; Stein, PD; Yin, X; Zahler, R; Zhang, R; Zhao, R; Zhuang, S | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Askew, V; Atkinson, K; Auerbach, B; Bakker-Arkema, R; Barclay, P; Bi, YA; Boustany, C; Bowles, DM; Boyles, DC; Bush, MR; Cheng, XM; Chupka, J; Dillon, L; Duignan, DB; El-Kattan, A; Erasga, N; Feng, B; Goosen, TC; Hanselman, JC; Hutchings, R; Kennedy, R; Kimoto, E; Kindt, E; Kowala, M; Lai, Y; Larsen, SD; Le, V; Lee, C; Lin, Z; Litchfield, J; Lu, G; Mandema, JW; Milad, M; Olsen, K; Pfefferkorn, JA; Robertson, A; Sahasrabudhe, V; Scialis, R; Sekerke, C; Tait, BD; Trivedi, BK | 1 |
| Amano, N; Maeda, K; Moriwaki, T; Nakakariya, M; Ono, M; Sugiyama, Y | 1 |
| Aiello, R; Ammirati, M; Aspnes, G; Atkinson, K; Baker, L; Barucci, N; Bian, J; Bourassa, P; Bourbonais, F; Cabrera, O; Chen, J; D'Aquila, T; Dasilva-Jardine, P; Derksen, DR; Duignan, DB; El-Kattan, A; Feng, B; Filipski, KJ; Guzman-Perez, A; Haddish-Berhane, N; Jones, CS; Knafels, J; Kosa, RE; Landro, JA; Lapworth, AL; Liras, S; Litchfield, J; Liu, S; Macdougall, M; Minich, ML; Murdande, S; Pettersen, J; Pfefferkorn, JA; Risley, H; Robertson, AS; Rolph, TP; Stevens, BD; Sweet, L; Tan, B; Treadway, JL; Tu, M; Varma, MV; Yao, L; Zavadoski, WJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Buckley, DB; Funk, RS; Hensley, T; Kazmi, F; Loewen, GJ; Parkinson, A; Pope, C | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for pravastatin and rosuvastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
15 other study(ies) available for pravastatin and rosuvastatin
| Article | Year |
|---|---|
Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Topics: Animals; Arteriosclerosis; Cholesterol, LDL; Clinical Trials as Topic; Drug Evaluation, Preclinical; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Molecular Structure; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2001 |
Binding thermodynamics of statins to HMG-CoA reductase.
Topics: Atorvastatin; Binding Sites; Calorimetry; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Pravastatin; Protein Binding; Pyridines; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Thermodynamics | 2005 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hyper
Topics: Animals; Cholesterol, LDL; Cricetinae; Guinea Pigs; Hepatocytes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; In Vitro Techniques; Liver; Male; Mesocricetus; Muscle Cells; Pyrazoles; Rats; Stereoisomerism; Structure-Activity Relationship | 2008 |
Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors.
Topics: Animals; Atorvastatin; Combinatorial Chemistry Techniques; Disease Models, Animal; Fluorobenzenes; Hepatocytes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Molecular Structure; Muscle Cells; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with
Topics: Administration, Oral; Animals; Biological Availability; Chemical and Drug Induced Liver Injury; Cholesterol; Crystallography, X-Ray; Dogs; Female; Guinea Pigs; Haplorhini; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Liver; Models, Molecular; Muscle Cells; Pyrimidines; Rats; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship; Triazoles | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Discovery of novel hepatoselective HMG-CoA reductase inhibitors for treating hypercholesterolemia: a bench-to-bedside case study on tissue selective drug distribution.
Topics: Animals; Cells, Cultured; Dogs; Dose-Response Relationship, Drug; Drug Discovery; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Imidazoles; Inhibitory Concentration 50; Liver; Molecular Structure; Pyrazoles; Rats; Tissue Distribution | 2011 |
In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
Topics: Angiotensin Receptor Antagonists; Animals; beta-Lactams; Biliary Tract; Biological Transport; Cells, Cultured; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pharmaceutical Preparations; Rats; Rats, Sprague-Dawley; Topotecan | 2012 |
Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.
Topics: Allosteric Site; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dogs; Enzyme Activators; Glucokinase; Haplorhini; Hepatocytes; Humans; Hypoglycemic Agents; Imidazoles; In Vitro Techniques; Insulin-Secreting Cells; Male; Models, Molecular; Nicotinic Acids; Organic Anion Transporters; Protein Binding; Rats; Rats, Sprague-Dawley; Rats, Wistar; Stereoisomerism; Structure-Activity Relationship; Tissue Distribution | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
Topics: Adrenergic beta-Antagonists; Amines; Ammonium Chloride; Antidepressive Agents, Tricyclic; Atorvastatin; Cell Line, Transformed; Diuretics; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imipramine; Lysosomes; Monensin; Nigericin; Propranolol; Pyrroles | 2013 |